Tariffs have become a recurring fault line in global trade policy—difficult to predict
but impossible to ignore as a‘new normal’. For the medical device industry, where
cross-border supply chains are foundational and regulatory compliance is non-
negotiable, the threat of trade disruptions introduces operational and strategic stress.
There is also a case for supply chains running through Asia still remain relevant and
irreplaceable today. To gauge how prepared the sector is, we surveyed 181 professionals
across the medical manufacturing ecosystem, from contract manufacturers and R&D
specialists to regulatory leaders and corporate executives.